Xtrava Health Receives Emergency Use Authorization for their Rapid SPERA™ COVID-19 Ag Test
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Stay updated with breaking news from Sameh Sarhan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
SANTA CLARA, Calif., Oct. 22, 2021 /PRNewswire/ -- Xtrava Health, a health technology company, today announced the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization
Share this article Share this article SANTA CLARA, Calif., April 28, 2021 /PRNewswire/ -- Xtrava Health, a health technology company, today announced it has been awarded a $6.2 million contract by the National Institutes of Health (NIH) under the Rapid Acceleration of Diagnostics (RADx SM) initiative to expedite the launch of its SPERA™ COVID-19 antigen test. Xtrava Health is one of the companies selected from a pool of more than 700 RADx applicants for the scale-up phase of the initiative. This contract follows months of meeting milestones and vetting Xtrava Health's technology and scale-...